CTOs on the Move


 
IQuum is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.iquum.com
  • 700 Nickerson Rd
    Marlborough, MA USA 01752
  • Phone: 508.970.0099

Executives

Name Title Contact Details

Similar Companies

EnviroLogix

Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.

Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.

CytomX

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company`s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc.

Dendritic NanoTechnologies

Dendritic NanoTechnologies is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.